A wide variety of approaches, all using gene transfer, have been tested experimentally as alternative means to vaccinate against cancer, either prophylactically or therapeutically. These include both ex vivo and in vivo gene transfer to tumour and/or non‐tumour cells, using both viral and non‐viral vectors. The transferred DNA has varied widely as well, including genomic or cDNA encoding tumour‐associated or oncofoetal antigens, cytokines, histocompatibility molecules, and costimulatory molecules. Several of these approaches have been applied in human clinical trials. This review summarizes those approaches, then compares and evaluates various methods using cytokine DNA in conjunction with autologous tumour cells, with particular emphasis on particle‐mediated gene transfer via a gene gun. Finally, prospects and needs for further development are discussed.